Mexico

Antibioticos De Mexico, S. A. De C. V.

An EMIS Company Report EMIS is a Euromoney Institutional Investor plc company USD 9.95 Industry: Pharmaceutical and Medicine Manufacturing Available in: English & Spanish Format: PDF Download Buy full report

What’s included?

This report extracts all available information about this company from EMIS' database of company information. The Table of Contents on the right indicates the categories of information that will be included in your report upon purchase.

Download a sample report

Company Tear Sheet (locked content will be provided in the purchased report)

Contact Information

Headquarters
Calle De Las Flores No. 56, Colonia Pueblo La Candelaria
Mexico City - Coyoacan ; Federal District of Mexico City; Map
Postal Code: 04380

Company Description
Antibioticos de Mexico - AMSA - is a company engaged in the manufacture and marketing of generic drugs in various therapeutic lines, including highly specialized (Hospital), analgesics, antibiotics, antidiabetics, antihypertensives and Ophthalmic, among others.
NAICS Industry Classification
Key Executives
Ownership Details

You’re in good company

EMIS company reports are used extensively by the world’s biggest companies, financial institutions, professional service companies and universities to assess businesses in emerging markets.

800,000+

company profiles

We have information on both public and private companies across 125 countries.

2,000+

clients

EMIS is the go-to information source on emerging market companies for the world’s most prestigious businesses.

Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

REQUEST A DEMO
Contact us to learn more about our business solutions.
FOLLOW US
Sign up to our newsletter

Make sure you’re not the last to know by getting the latest insights on emerging markets straight to your inbox.